Virtual Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Douglas Johnson, M.D., MSCI
Associate Professor of Medicine
Clinical Director, Melanoma Program
Ingram Cancer Center
Vanderbilt University
Virtual Pioneers in Biomedical Research Seminar: Dissecting Toxicities of Immune Checkpoint Inhibitors
Nov. 19, 2021
11:00 a.m. to 12:00 p.m.
Archived video
About this Seminar
Anti-PD-1 therapy has dramatically altered cancer treatments, but many unanswered questions remain. First, the need for more accurate biomarkers to provide clues to the pathogenesis of response and resistance, and to more accurately assign patients to effective treatment remains a key unmet need. Tumor cell expression of MHC class II and tumor mutational burden are two potential markers of response. Second, patients treated with anti-PD-1, especially when used in combination, frequently experience severe immune-related toxicities. Identifying patients at risk, clinically phenotyping clinical events, and determine effective treatment strategies remain unmet needs. In this presentation, Dr. Johnson will discuss his lab's work in identifying anti-PD-1 biomarkers, particularly focusing on MHC-II and tumor mutational burden, and in characterizing anti-PD-1 toxicities.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
-
Home Item
In Person at CNRIC: Hyperactivation of an RNA Binding Protein by Cancer-associated Mutations , homeApril 19, 11:00 a.m., Collaboratory, Children's National Research and Innovation Campus, Washington, D.C. | Daniel Dominguez, Ph.D., Assistant Professor, Pharmacology, UNC School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center (DC)
-
Home Item
In Person Seminar: Our Mass Spectrometry Screening Studies in the Mouse and Human Hearts in Health and Disease , homeApril 26, 2024, 11 a.m. | Anthony Gramolini, Ph.D., Professor, Physiology and Translational Biology and Engineering, Ted Rogers Centre for Heart Research, University of Toronto | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home Item
In Person Seminar: Regulation of Mitochondrial Parameters in Skeletal Muscle , homeMay 3, 2024, 11:00 a.m. | Glenn Rowe, Ph.D., Associate Professor of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research
-
Home Item
Planning the Future of Environmental Health Sciences , homeMay 9, 2024, 5:30 p.m. (Reception at 5 p.m.) | Rick Woychik, Ph.D., Director, National Institute of Environmental Health Sciences, National Institutes of Health | Maury Strauss Distinguished Public Lecture
-
Home Item
In Person Seminar: Flavors in Tobacco and Nicotine Products: Science-based Regulation , homeMay 10, 2024, 11:00 a.m. | Suchitra Krishnan-Sarin, Ph.D., Albert E. Kent Professor of Psychiatry, Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Health Behaviors Research and the Addiction Recovery Research Center
-
Home Item
CANCELLED: In Person Seminar: Sex Influences on Brain and Body: An Issue That is Here to Stay , homeMay 17, 2024, 11:00 a.m. | Larry Cahill, Ph.D., Professor, Neurobiology and Behavior, University of California, Irvine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research